Elutia (NASDAQ:ELUT – Get Free Report) issued its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02), FiscalAI reports. The firm had revenue of $3.11 million for the quarter, compared to the consensus estimate of $3.00 million.
Elutia Stock Down 1.0%
Shares of Elutia stock traded down $0.01 during trading on Thursday, reaching $1.04. The company’s stock had a trading volume of 107,560 shares, compared to its average volume of 195,247. The business’s 50-day moving average price is $1.10 and its 200-day moving average price is $0.91. Elutia has a 52 week low of $0.50 and a 52 week high of $2.64. The firm has a market cap of $44.50 million, a PE ratio of 1.27 and a beta of 0.75.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. Deerfield Management Company L.P. acquired a new stake in shares of Elutia in the third quarter valued at approximately $1,221,000. XTX Topco Ltd bought a new stake in shares of Elutia during the 4th quarter valued at $71,000. Citadel Advisors LLC acquired a new stake in shares of Elutia during the 3rd quarter worth $50,000. Renaissance Technologies LLC increased its position in shares of Elutia by 64.7% in the fourth quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock worth $71,000 after purchasing an additional 40,123 shares during the period. Finally, Virtu Financial LLC bought a new stake in Elutia during the third quarter worth about $26,000. Institutional investors and hedge funds own 74.03% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on ELUT
Elutia Company Profile
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.
The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
Featured Stories
- Five stocks we like better than Elutia
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
